title: [Acute myocardial infarction in Charleroi: evolution of risk factors and therapeutic practices].
abstract: OBJECTIVE
  The aim of the study consists in analyzing the evolution of acute coronary risk factors as well as the 28 days case fatality and the therapeutic practices over 12 years of follow-up in Charleroi. The factors influencing the mortality of these patients are also investigated.
  
  
  METHODS
  The Charleroi register of ischaemic cardiopathies is the oldest register of infarctions in the French-speaking community of Belgium. Analyses presented hereafter relate only patients in the 25-69-year age range over time from 1998 to 2009. Some analysis was extended to 25-74-year range. Treatment and risk factors evolutions over time were analysed using Chi(2) tests. Logistic regression was used to identify factors influencing 28 days mortality.
  
  
  RESULTS
  The analysis shows a significant decline in 28 days mortality. A marked increase in the prevalence of hypertension and hypercholesterolemia is highlighted as well as an increase of utilization of percutaneous transluminal coronary angioplasty (PTCA) between 1998 and 2009. The use of ß-blockers and antiplatelet drugs remained fairly stable between 1998 and 2009 with approximately 75% and 90% of the patients treated, respectively. The factors associated with fatality were specifically age of patients, antecedents of diabetes and antecedents of myocardial infarction, hypercholesterolaemia as well as oral antiplatelet drugs, ß-blockers therapies and PTCA.
  
  
  CONCLUSIONS
  The evolution of the therapeutic data on AMI in this register confirms that PTCA becomes the main coronary reperfusion. Angiotensin-converting enzyme inhibitors were without effect on mortality.
authors.affiliation: Centre de recherche épidémiologie, biostatistiques et recherche clinique, École de santé publique, université Libre de Bruxelles (ULB), route de Lennik 808, CP 596, 1070 Bruxelles, Belgique. Electronic address: ph.collart@skynet.be.
authors.forename: P
authors.initials: P
authors.lastname: Collart
authors.forename: Y
authors.initials: Y
authors.lastname: Coppieters
authors.forename: M
authors.initials: M
authors.lastname: Dramaix
authors.forename: A
authors.initials: A
authors.lastname: Levêque
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000401:mortality* / Q000706:statistics & numerical data*; D001530:Belgium / Q000453:epidemiology; D048909:Diabetes Complications / Q000453:epidemiology / Q000628:therapy; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000453:epidemiology; D006973:Hypertension / Q000150:complications / Q000453:epidemiology; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology / Q000401:mortality* / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D015995:Prevalence; D012307:Risk Factors; D017678:Sex Distribution; D012907:Smoking / Q000009:adverse effects; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D010975:Platelet Aggregation Inhibitors
keywords: Acute myocardial infarction; Facteurs de risque; Infarctus du myocarde; MONICA; Register; Registre; Risk factors; Traitement; Treatment